The product contains a combination of Tamsulosin 0.4 mg and Dutasteride 0.5 mg, both of which are used in treatment protocols for benign prostatic enlargement in men.

The launch event featured a series of scientific lectures delivered by a distinguished group of specialists:

• Dr. Mamoun Al-Zabda
• Dr. Khalid Al-Sadiq
• Dr. Zaid Abu Ghosh
• Dr. Samer Al-Jizawi

The event was moderated by Dr. Ghassan Talahmeh, President of the Jordanian Association of Urology and Kidney Surgery.

The lectures addressed the scientific aspects of the treatment of benign prostatic enlargement and the latest medical practices in this field.